医学
头孢地尼
阿莫西林
头孢呋辛
头孢泊肟
加药
抗菌剂
头孢曲松
头孢菌素
急性中耳炎
内科学
中耳炎
抗生素
微生物学
外科
生物
作者
Michael E. Pichichero,Janet R. Casey
出处
期刊:PubMed
[National Institutes of Health]
日期:2005-04-01
卷期号:54 (4): 313-22
被引量:11
摘要
High-dose amoxicillin (80 to 90 mg/kg/d divided twice daily) remains the drug of choice for treatment of acute otitis media despite increasing antimicrobial resistance. For persistent or recurrent acute otitis media, guidelines recommend high-dose amoxicillin/clavulanate (90/6.4 mg/kg/d), cefdinir, cefprozil, cefpodoxime, cefuroxime, or ceftriaxone. Increasing the dose of amoxicillin does not cover infection with beta-lactamase-producing pathogens; add the beta-lactamase inhibitor clavulanate to amoxicillin, or choose a cephalosporin with good activity against S pneumoniae and good beta-lactamase stability. Key factors for enhancing compliance are taste of suspension, dosing frequency, and duration of therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI